الفهرس 
ACUTE MYOCARDIAL I NFARCTIONOnly 14 pages are availabe for public view
 |  | from | 151 |  |  |
| | | from | 151 | | |
Abstract
Background: Percutaneous coronary intervention (PCI) is extensively used as a reperfusion strategy for coronary artery disease. Although this procedure is relatively safe and the procedure-related complications have markedly decreased over the years and with increased experience, myocardial injury can still occur. Recently it was found that pretreatment with statins may significantly reduce major adverse cardiac events (MACE) in patients undergoing PCI.
Methods: The study includes a total of 40 patients will be randomly assigned to group A of 20 patients which received 40 mg Rosuvastatin high dose-loading before PCI or group B which received no statin pretreatment (Control group). Detailed clinical and laboratoty history of the patients were carried out. High sensitivity C-reactive protein (hs-CRP) level will be withdrawn from both groups Post-PCI (24h after PCI) and compared to pre-PCI results. Follow up of major adverse cardiac events (MACE) including primary and secondary end-point of non fatal MI, cardiovascular mortality, stroke, major bleeding, & need for revascularization that occurred during in-hospital stay and within 30 days after PCI.
Results: There were no statistically significant differences between the 2 study groups as regards the demographic findings. Numerically, procedural characteristics appear to be similar and therefore there was no statistical significance to report. Some results were notable especially post-procedural serum Creatinine, the pre and post procedural Hs-CRP and the MACCE. Post-procedural serum Creatinine was significantly lower in the Rosuvastatin group (A). This had a statistical significance with a P value of 0.055 proving that Rosuvastatin high dose pre-loading before PCI had renal protective effects and helped prevent Contrast Induced Acute Kidney Injury (CI-AKI). Considering Hs-CRP numerical values, in group A they were significantly lower hinting the role of Rosuvastatin as an anti-inflammatory agent. However, the percentage change in comparison to group B’s numbers were not statistically significant. Finally, a total MACCE of four cases or 20% in group B in comparison to 0% among Rosuvastatin group A. However, this numerical significance failed to translate into a significant statistical result with a P value of 0.147 and so no positive conclusion could be drawn from this data to formulate a sound recommendation.
Conclusion: High dose Rosuvastatin pre-loading in patients undergoing PPCI, resulted in a numerical reduction in MACCE and lower percentage elevation of hs-CRP but with no statistical significance. However it did confirm the efficacy of statin pre-treatment for the prevention of Contrast-Induced Acute Kidney Injury in patients undergoing Percutaneous Coronary Intervention